TOP NEWS
CALL to participate in IPA Project Every Move Counts
At International Pompe Day the International Pompe Association kicked off the Every Move Counts project. This project focuses on raising awareness of the importance of movement. We all have different abilities and levels of disability, but the important thing to...
OTHER NEWS
Genzyme’s Pompe Program Update
An update by Genzyme regarding treatment for Pompe disease. Q: What is the status of the Pompe program? Genzyme has made strong progress within its Pompe disease program since its decision earlier this year to move forward with an internally developed product...
IPA/Genzyme News—September 24, 2002
IBaarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone conference of September 24 2002. We discussed issues concerning the production, the transition, new trials and the meeting with the Erasmus University, VSN,...
Transgenic Enzyme Production to Cease
In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzyme) patients to the CHO derived product. Three of the nine patients (infantile patients in the Netherlands) will remain on the transgenic enzyme until April 2003, when supply will be...
IPA/Genzyme Meeting
Board members of the IPA, the International Pompe Association, met with key representatives of Genzyme in Cambridge, Massachusetts on April 16-17, 2002. The IPA members in attendance were: Randall House, AMDA-US; Marylyn House, AMDA-US, Ria Broekgaarden, VSN-The...
Genzyme Press Release
Excerpt From Genzyme’s April 17, 2002 Press Release Pompe Update Genzyme is moving forward aggressively with its program to develop an effective therapy for Pompe disease. Genzyme has invested significant resources over the past four years pursuing the most promising...
Letter from Vice President of Genzyme
Following is a letter sent to the IPA by Jan van Heek, Executive Vice President of Genzyme, for release prior to the VSN Pompe Patient Conference which took place on March 9, 2002. in the Netherlands. Dear Friends, On Saturday, March 9th, 2002, I will be speaking at...
IPA Board Meeting – February 18-19, 2002
The first official IPA Board Meeting occurred in Rotterdam, The Netherlands on Feb. 18-19, 2002. Future agendas were planned and the following committees were formed. Communications—Kevin O’Donnell, Alan Muir, Marylyn House Patient Organizations—Maryze Schoneveld,...
Letter from IPA Chairman to Pompe Patients
The International Pompe Association (IPA) board will meet on February 18-19th, 2002. Representatives of scientific/medical teams and Genzyme will attend. The following issues will be discussed: 1. Finalize the universal patient questionnaire to be distributed in the...
Genzyme Acquires Manufacturing Facility in Europe
October 2001—CAMBRIDGE, Mass.—Genzyme Corporation announced today that it has acquired certain assets of Pharming N.V., the Belgian subsidiary of the Pharming Group currently operating under a court-supervised receivership. These assets include a 70,000 square foot...
Genzyme to Acquire Novazyme Pharmaceuticals
Proprietary Glycoprotein Technology Platform Will Advance Lysosomal Storage Disorder Programs Excerpt from August 7, 2001 Press Release Genzyme Corp. and privately held Novazyme Pharmaceuticals Inc. today announced a definitive merger agreement under which Novazyme...
Acid Maltase Deficiency Association
For the AMDA videos: All Rights reserved. No part of the AMDA's videos may be reproduced or transmitted in any form or by any means, electronic or mechanical, without the written permission of the copyright holder.
If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:
info@amda-pompe.org
THE AMDA
PO Box 700248
San Antonio, Texas 78270 USA